Loading

Commentary Open Access
Volume 1 | Issue 3 | DOI: https://doi.org/10.46439/cardiology.1.014

Implications of ATPCI study on trimetazidine use in clinical practice

  • 1Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India
  • 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
+ Affiliations - Affiliations

Corresponding Author

Jamshed Dalal, jjdalal@hotmail.com

Received Date: July 24, 2021

Accepted Date: August 27, 2021

Abstract

The ATPCI (efficAcy and safety of Trimetazidine in patients with angina pectoris treated by Percutaneous Coronary Intervention) study reported similar primary outcomes between trimetazidine and placebo groups in patients with angina who recently had a percutaneous coronary intervention, but the results of this study reconfirmed the safety of trimetazidine. The study has certain limitations in terms of design and inclusion of the target patient population. Here, we discuss these limitations and their implications on trimetazidine use in routine clinical practice.

Keywords

Trimetazidine, Percutaneous coronary intervention, Angina pectoris

Author Information X